drug · small molecule

LPCN-1144

Marketedupdated 3mo ago

by $LPCN Lipocine Inc.🔗 ChEMBL

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 10 investigational indications.

targets

Androgen receptor

all catalysts(0)

nothing on the calendar yet

Trials studying LPCN-1144

phase2Testosterone Treatment in Men With Chronic Kidney Diseaserecruitingn=20
phase2Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancercompletedn=15
phase4A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Monthsactive not recruitingn=110
phase2TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosisrecruitingn=40
phase4Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadismrecruitingn=32
phase4Patient Satisfaction After Switching to Oral Testosterone Undecanoatecompletedn=41

Patent cliff

source: FDA Orange Book

first barrier falls

Jan 6, 2027

138 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (64)

Apr 28, 2041formulationUS 11464735
Mar 29, 2041formulationUS 12403146
Mar 29, 2041formulationUS 12403146
Mar 29, 2041formulationUS 12403146
Oct 16, 2040formulationUS 12011503
Apr 12, 2039method-of-use (U-1103)US 11564933
Apr 12, 2039method-of-use (U-1103)US 11564933
Apr 12, 2039method-of-use (U-1103)US 11564933
Feb 21, 2039method-of-use (U-4194)US 12310978
Nov 28, 2037method-of-use (U-1500)US 11559530
Mar 15, 2033formulationUS 11617758
Mar 15, 2033formulationUS 11617758
Mar 15, 2033formulationUS 11617758
Mar 15, 2033formulationUS 12357643
Mar 15, 2033formulationUS 12357643
Mar 15, 2033formulationUS 12357643
Dec 31, 2030formulationUS 105760894.4y
Dec 31, 2030formulationUS 105760894.4y
Dec 31, 2030formulationUS 105760894.4y
Dec 31, 2030formulationUS 105760904.4y
Dec 31, 2030formulationUS 105760904.4y
Dec 31, 2030formulationUS 105760904.4y
Dec 31, 2030formulationUS 115901464.4y
Dec 31, 2030formulationUS 115901464.4y
Dec 31, 2030formulationUS 115901464.4y
Dec 20, 2030formulationUS 84923694.3y
Dec 20, 2030formulationUS 84923694.3y
Dec 20, 2030formulationUS 84923694.3y
Nov 30, 2030method-of-use (U-1500)US 102264734.3y
Nov 30, 2030method-of-use (U-1500)US 107167944.3y
Nov 30, 2030method-of-use (U-1500)US 113115554.3y
Nov 30, 2030method-of-use (U-1500)US 113642494.3y
Nov 30, 2030method-of-use (U-1500)US 114330834.3y
Nov 30, 2030method-of-use (U-1500)US 99435274.3y
Nov 30, 2030method-of-use (U-1500)US 99499854.3y
Apr 12, 2030method-of-use (U-2506)US 105432193.6y
Apr 12, 2030method-of-use (U-2506)US 105432193.6y
Apr 12, 2030method-of-use (U-2506)US 105432193.6y
Apr 12, 2030compositionUS 106176963.6y
Apr 12, 2030compositionUS 106176963.6y
Apr 12, 2030compositionUS 106176963.6y
Apr 12, 2030method-of-use (U-2506)US 111794033.6y
Apr 12, 2030method-of-use (U-2506)US 111794033.6y
Apr 12, 2030method-of-use (U-2506)US 111794033.6y
Apr 12, 2030method-of-use (U-3420)US 114264163.6y
Apr 12, 2030method-of-use (U-3420)US 114264163.6y
Apr 12, 2030method-of-use (U-3420)US 114264163.6y
Apr 12, 2030formulationUS 87789163.6y
Apr 12, 2030formulationUS 87789163.6y
Apr 12, 2030formulationUS 87789163.6y
Mar 29, 2029formulationUS 82416642.6y
Mar 29, 2029formulationUS 82416642.6y
Mar 29, 2029formulationUS 82416642.6y
Jan 8, 2029formulationUS 113049602.4y
Jan 8, 2029formulationUS 87789222.4y
Jan 8, 2029method-of-use (U-1500)US 88656952.4y
May 8, 2027method-of-use (U-1500)US 8338395260d
Mar 14, 2027formulationUS 7718640205d
Jan 6, 2027method-of-use (U-2506)US 11331325138d
Jan 6, 2027method-of-use (U-2506)US 11331325138d
Jan 6, 2027method-of-use (U-2506)US 11331325138d
Apr 14, 2026compositionUS 11179402
Apr 14, 2026compositionUS 11179402
Apr 14, 2026compositionUS 11179402

News(0)

no news has mentioned this drug yet

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 1m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

LPCN-1144

Marketedupdated 3mo ago

by $LPCN Lipocine Inc.🔗 ChEMBL

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 10 investigational indications.

targets

Androgen receptor

all catalysts(0)

nothing on the calendar yet

Trials studying LPCN-1144

phase2Testosterone Treatment in Men With Chronic Kidney Diseaserecruitingn=20
phase2Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancercompletedn=15
phase4A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Monthsactive not recruitingn=110
phase2TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosisrecruitingn=40
phase4Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadismrecruitingn=32
phase4Patient Satisfaction After Switching to Oral Testosterone Undecanoatecompletedn=41

Patent cliff

source: FDA Orange Book

first barrier falls

Jan 6, 2027

138 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (64)

Apr 28, 2041formulationUS 11464735
Mar 29, 2041formulationUS 12403146
Mar 29, 2041formulationUS 12403146
Mar 29, 2041formulationUS 12403146
Oct 16, 2040formulationUS 12011503
Apr 12, 2039method-of-use (U-1103)US 11564933
Apr 12, 2039method-of-use (U-1103)US 11564933
Apr 12, 2039method-of-use (U-1103)US 11564933
Feb 21, 2039method-of-use (U-4194)US 12310978
Nov 28, 2037method-of-use (U-1500)US 11559530
Mar 15, 2033formulationUS 11617758
Mar 15, 2033formulationUS 11617758
Mar 15, 2033formulationUS 11617758
Mar 15, 2033formulationUS 12357643
Mar 15, 2033formulationUS 12357643
Mar 15, 2033formulationUS 12357643
Dec 31, 2030formulationUS 105760894.4y
Dec 31, 2030formulationUS 105760894.4y
Dec 31, 2030formulationUS 105760894.4y
Dec 31, 2030formulationUS 105760904.4y
Dec 31, 2030formulationUS 105760904.4y
Dec 31, 2030formulationUS 105760904.4y
Dec 31, 2030formulationUS 115901464.4y
Dec 31, 2030formulationUS 115901464.4y
Dec 31, 2030formulationUS 115901464.4y
Dec 20, 2030formulationUS 84923694.3y
Dec 20, 2030formulationUS 84923694.3y
Dec 20, 2030formulationUS 84923694.3y
Nov 30, 2030method-of-use (U-1500)US 102264734.3y
Nov 30, 2030method-of-use (U-1500)US 107167944.3y
Nov 30, 2030method-of-use (U-1500)US 113115554.3y
Nov 30, 2030method-of-use (U-1500)US 113642494.3y
Nov 30, 2030method-of-use (U-1500)US 114330834.3y
Nov 30, 2030method-of-use (U-1500)US 99435274.3y
Nov 30, 2030method-of-use (U-1500)US 99499854.3y
Apr 12, 2030method-of-use (U-2506)US 105432193.6y
Apr 12, 2030method-of-use (U-2506)US 105432193.6y
Apr 12, 2030method-of-use (U-2506)US 105432193.6y
Apr 12, 2030compositionUS 106176963.6y
Apr 12, 2030compositionUS 106176963.6y
Apr 12, 2030compositionUS 106176963.6y
Apr 12, 2030method-of-use (U-2506)US 111794033.6y
Apr 12, 2030method-of-use (U-2506)US 111794033.6y
Apr 12, 2030method-of-use (U-2506)US 111794033.6y
Apr 12, 2030method-of-use (U-3420)US 114264163.6y
Apr 12, 2030method-of-use (U-3420)US 114264163.6y
Apr 12, 2030method-of-use (U-3420)US 114264163.6y
Apr 12, 2030formulationUS 87789163.6y
Apr 12, 2030formulationUS 87789163.6y
Apr 12, 2030formulationUS 87789163.6y
Mar 29, 2029formulationUS 82416642.6y
Mar 29, 2029formulationUS 82416642.6y
Mar 29, 2029formulationUS 82416642.6y
Jan 8, 2029formulationUS 113049602.4y
Jan 8, 2029formulationUS 87789222.4y
Jan 8, 2029method-of-use (U-1500)US 88656952.4y
May 8, 2027method-of-use (U-1500)US 8338395260d
Mar 14, 2027formulationUS 7718640205d
Jan 6, 2027method-of-use (U-2506)US 11331325138d
Jan 6, 2027method-of-use (U-2506)US 11331325138d
Jan 6, 2027method-of-use (U-2506)US 11331325138d
Apr 14, 2026compositionUS 11179402
Apr 14, 2026compositionUS 11179402
Apr 14, 2026compositionUS 11179402

News(0)

no news has mentioned this drug yet

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 1m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

LPCN-1144

targets

all catalysts(0)

Trials studying LPCN-1144

Patent cliff

patents (64)

News(0)

Report a data issue

comments(0)

LPCN-1144

targets

all catalysts(0)

Trials studying LPCN-1144

Patent cliff

patents (64)

News(0)

Report a data issue

comments(0)